SCHEMBL6042813

SCHEMBL6042813

COS(=O)(=O)O.Cc1c(C(=O)O)ccc2cccc(O)c12

nearest known ligand 0.42

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
HSD17B10 Q99714 3/20 0.42
KMT2A Q03164 3/20 0.42
TSHR P16473 2/20 0.42
MEN1 O00255 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
GRIN2D O15399 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
LMNA P02545 1/20 0.37
ALOX12 P18054 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
LDHA P00338 1/20 0.36
TLR2 O60603 1/20 0.36
TLR1 Q15399 1/20 0.36
TLR6 Q9Y2C9 1/20 0.36
PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045135 0.79 CDC25B (0.41) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL6043398 0.73 CA12 (0.41) ALDH1A1TSHRMAPTLDHACA12
SCHEMBL23909561 0.72 HSD17B10 (0.45) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL3389763 0.72 ALDH1A1 (0.69) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL8944544 0.71 KDM4E (0.53) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL12486671 0.70 HSD17B10 (0.62) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL23909535 0.70 MEN1 (0.49) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL23909554 0.70 PARP1 (0.49) ALDH1A1KDM4EHSD17B10KMT2ATSHR
Propylamine SCHEMBL28201098 0.70 TSHR (0.43) ALDH1A1KDM4EHSD17B10KMT2ATSHR
SCHEMBL689259 0.69 HSD17B10 (0.67) ALDH1A1KDM4EHSD17B10KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 ALDH1A1 2504/4885KDM4E 2501/4885HSD17B10 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.